Speaker illustration

Ms Britt Heidemann

University Medical Center Utrecht, Utrecht (Netherlands (The))

Effect of evolocumab versus placebo added to standard lipid-lowering therapy on fasting and post fat load lipids and lipoproteins in familial dysbetalipoproteinemia

Event: ESC Congress 2022

Topic: Drug therapy

Session: Optimal risk factor therapy in high risk patients


Risk factors for the presence and development of Familial Dysbetalipoproteinemia in subjects from the general population with an APOE2E2 genotype

Event: ESC Congress 2020

Topic: Lipids

Session: Genetic Predisposition and Management of Dyslipidemia


Remnant cholesterol increases the risk for recurrent vascular events independent of ldl-cholesterol in patients with clinical manifest vascular disease.

Event: ESC Congress 2019

Topic: Lipids

Session: Lipids / Cardiovascular risk prediction / Life style


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb